美国「鼻烟壶优先」血液透析通路策略的当代结局
本研究在美国单中心对55例需血液透析的终末期肾病或透析前患者采用鼻烟壶优先策略建立动静脉内瘘,1年次级通畅率92.3%,临床成熟率83.7%,功能成熟率85.6%,多数患者需辅助干预促进成熟。
要点
- 鼻烟壶优先策略在美国患者中可行,1年次级通畅率92.3%。
- 1年临床成熟率83.7%,功能成熟率85.6%。
- 糖尿病与临床成熟延迟相关,较大动脉直径与较早成熟相关。
核心结论
- 鼻烟壶优先策略是美国需血液透析患者建立远端通路的可行选择。
- 多数患者需要后续辅助干预以促进通路成熟。
研究设计与样本
- 单中心前瞻性队列研究,2016年1月至2019年8月纳入55例终末期肾病或透析前患者。
- 由血管外科和肾内科团队评估后采用鼻烟壶优先策略建立动静脉内瘘。
- 采用生存分析评估主要无辅助通畅率、次级通畅率及临床和功能成熟,Cox回归分析成熟延迟危险因素。
主要发现
- 中位随访369天(IQR 166-509天),主要无辅助通畅中位生存90天(95%CI 79-111天)。
- 1年次级通畅率92.3%(95%CI 85.3%-99.9%),临床成熟率83.7%(95%CI 66.8%-91.9%),功能成熟率85.6%(95%CI 63.3%-94.4%)。
- 透析前建立内瘘且研究期间开始透析的患者中87.5%成功用鼻烟壶内瘘起始透析。
- 第一年内中位干预次数2次(IQR 0-7次),其中经皮血管成形术占46.9%,侧支结扎占31.2%。
临床怎么用
- 对所有解剖条件合适的患者可优先考虑鼻烟壶内瘘以保留近端血管资源。
- 应预期多数患者需辅助干预促进成熟,糖尿病和动脉直径较小者成熟可能延迟。
局限性
- 单中心、样本量55例,结果外推需谨慎。
- 部分分析样本量较小(如功能成熟分析n=40),置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Society for Vascular Surgery guidelines for permanent hemodialysis (HD) access creation recommend prioritizing the most distal possible autogenous access to minimize complications and preserve more proximal options. The "snuffbox" arteriovenous fistula (AVF) is the most distal radial artery-cephalic vein AVF. Despite the theoretical benefits of the snuffbox approach, recent trends have been toward upper arm access. Our study sought to investigate the feasibility of a snuffbox-first strategy for HD access in all anatomically appropriate candidates. METHODS: From January 2016 to August 2019, all patients with end-stage renal disease (ESRD) or pre-ESRD under consideration for HD access were evaluated for a snuffbox-first approach by a team of vascular surgeons and nephrologists at a single, urban academic medical center in the United States. Data were collected prospectively and supplemented by medical record review. A survival analysis was performed to evaluate primary unassisted and secondary patency and clinical and functional maturation. Patients were censored if they had received a kidney transplant or had died. Cox proportional hazards regression was used to determine the risk factors for prolonged clinical maturation and functional maturation. RESULTS: A total of 55 snuffbox AVFs were created. The median patient age was 60 years (interquartile range [IQR], 52-70 years), and 52.7% of the patients were men. The median follow-up was 369 days (IQR, 166-509 days). The median survival for primary unassisted patency was 90 days (95% confidence interval [CI], 79-111). Secondary patency at 1 year was 92.3% (95% CI, 85.3%-99.9%). The clinical maturation rate at 1 year was 83.7% (n = 55; 95% CI, 66.8%-91.9%), and the functional maturation rate at 1 year was 85.6% (n = 40; 95% CI, 63.3%-94.4%). Of the patients who were pre-ESRD at AVF creation and had initiated HD during the study period, 87.5% had successfully received incident HD with their snuffbox AVF. Twenty-four patients were receiving HD via a catheter at snuffbox creation. Of those patients, the functional maturation rate at 1 year was 82.5% (95% CI, 44.8%-94.4%). The patients had undergone a median of two interventions (IQR, zero to seven interventions) in the first year. Of these, 46.9% were percutaneous angioplasty and 31.2% were side-branch ligation. Diabetes was associated with slower AVF clinical maturation (multivariate hazard ratio, 0.35; 95% CI, 0.15-0.82; P = .016). A larger artery diameter was associated with earlier AVF clinical maturation (multivariate hazard ratio, 6.64; 95% CI, 2.11-20.9). CONCLUSIONS: A snuffbox-first approach to HD access is a viable option for distal access creation in a cohort of patients requiring HD in the United States. Subsequent ancillary interventions to facilitate access maturation were required for most patients.
引用
- Heindel P, Dieffenbach BV, Sharma G, et al. Contemporary outcomes of a "snuffbox first" hemodialysis access approach in the United States. J Vasc Surg. 2021. PMID: 33667611. doi:10.1016/j.jvs.2021.01.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。